Experts: Lumping Kratom and 7-OH Under One Name Creates Dangerous Confusion for Patients and Policymakers

Why it matters

Leading researchers say the blanket use of 'kratom' to describe both botanical leaf and high-potency synthetic 7-OH products is fueling misinformation in emergency medicine, public health tracking, and regulatory policy. Getting this distinction right affects both patient care and the scope of any legal action.

The big picture

Kratom-related emergency calls to poison control centers were largely stable for seven years before roughly doubling in 2025. Experts attribute much of the spike to 7-OH and its derivatives—compounds that are 30 to 40 times more potent at opioid receptors than the kratom alkaloid mitragynine. The DEA's August 2026 action targets those concentrated products, but the conversation has exposed how little systematic data exists because products have entered the market without FDA safety review.

Key findings

• Kratom-related emergency calls to poison control centers roughly doubled in 2025 after being stable for seven years
• Concentrated 7-OH is 30-40 times more potent at opioid receptors than mitragynine (kratom leaf's primary alkaloid) and more potent than morphine
• DEA's August 2026 action targets concentrated synthetic 7-OH products; it does not apply to botanical kratom leaf
• Researchers warn that banning 7-OH may push demand toward analog compounds like MGM-15, which is already in the scientific literature but has no animal safety data
• Both botanical kratom and synthetic 7-OH entered the market without a full FDA safety evaluation, limiting researchers' ability to characterize risk

What they say

"We can't just talk about kratom anymore," said Dr. Shravani Durbhakula of Vanderbilt University Medical Center. "We need to be talking about mitragynine versus 7-OH versus any other alkaloid that might be compounded." University of Florida professor Christopher McCurdy added: "This real sort of trash can designation for all of the products by clumping them together has created a great amount of confusion—not only in the medical establishment and in the consumer base, but in the toxicological and policy-making space."

Bottom line

Treating kratom and 7-OH as interchangeable terms is a clinical and regulatory error—experts say precise chemical distinctions are essential as overdose data mounts and federal scheduling takes effect.